Lifecore Biomedical Inc
NASDAQ:LFCR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.815
8.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Lifecore Biomedical Inc
Lifecore Biomedical Inc
Net Issuance of Debt
Lifecore Biomedical Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
Net Issuance of Debt
$1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-55%
|
CAGR 10-Years
39%
|
|
|
Hershey Co
NYSE:HSY
|
Net Issuance of Debt
$376.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
General Mills Inc
NYSE:GIS
|
Net Issuance of Debt
$829.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
Kellogg Co
NYSE:K
|
Net Issuance of Debt
-$1.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Kraft Heinz Co
NASDAQ:KHC
|
Net Issuance of Debt
-$38m
|
CAGR 3-Years
80%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Mondelez International Inc
NASDAQ:MDLZ
|
Net Issuance of Debt
-$837m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
11%
|
|
Lifecore Biomedical Inc
Glance View
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.
See Also
What is Lifecore Biomedical Inc's Net Issuance of Debt?
Net Issuance of Debt
1.6m
USD
Based on the financial report for Aug 25, 2024, Lifecore Biomedical Inc's Net Issuance of Debt amounts to 1.6m USD.
What is Lifecore Biomedical Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
39%
Over the last year, the Net Issuance of Debt growth was 13%.
You don't have any saved screeners yet
